What is the maximum intravenous dose of diazepam for acute seizure management in adults and children?

Maximum Dose of Intravenous Diazepam for Active Seizures

For adults with status epilepticus, administer 5–10 mg IV initially, repeating every 10–15 minutes up to a maximum cumulative dose of 30 mg. 1

Adult Dosing Protocol

• Initial dose: 5–10 mg IV, administered slowly over at least 2 minutes (1 minute per 5 mg) 1
• Repeat dosing: If seizures persist, repeat 5–10 mg IV every 10–15 minutes 1
• Maximum cumulative dose: 30 mg total within the initial treatment period 1
• Subsequent therapy: If necessary, diazepam may be repeated in 2–4 hours, though residual active metabolites persist and readministration requires careful consideration 1

The FDA label explicitly states that facilities for respiratory assistance must be readily available before IV administration. 1

Pediatric Dosing Protocol

Infants Over 30 Days and Children Under 5 Years

• Dose: 0.2–0.5 mg slowly IV every 2–5 minutes 1
• Maximum cumulative dose: 5 mg total 1
• Repeat in 2–4 hours if necessary 1

Children 5 Years and Older

• Dose: 1 mg IV every 2–5 minutes 1
• Maximum cumulative dose: 10 mg total 1
• Repeat in 2–4 hours if necessary 1

The American Academy of Pediatrics recommends 0.1–0.3 mg/kg IV every 5–10 minutes with a maximum of 10 mg per dose for pediatric status epilepticus. 2

Critical Administration Guidelines

Rate of Administration

• Inject slowly, taking at least 1 minute for each 5 mg (1 mL) given 1
• Rapid IV administration may precipitate seizures and cause pain at the IV site 2, 1

Vascular Access Considerations

• Do not use small veins such as those on the dorsum of the hand or wrist 1
• Extreme care must be taken to avoid intra-arterial administration or extravasation 1
• If direct IV administration is not feasible, inject slowly through infusion tubing as close as possible to the vein insertion 1

Route Preference

• The intravenous route is by far preferred for convulsing patients 1
• If IV administration is impossible, the intramuscular route may be used, though IM diazepam is not recommended by some sources due to tissue necrosis risk 2, 1
• Rectal diazepam (0.5 mg/kg up to 20 mg) may be useful when IV access is unavailable, though absorption is erratic 2

Safety Monitoring and Precautions

Respiratory Depression

• There is an increased incidence of apnea when diazepam is given rapidly IV or combined with other sedative agents 2
• Monitor oxygen saturation and respiratory effort continuously 2
• Be prepared to support ventilation 2
• Extreme caution must be exercised with individuals with chronic lung disease or unstable cardiovascular status 1

Flumazenil Availability

• Flumazenil should be immediately available to reverse life-threatening respiratory depression 2
• However, flumazenil also counteracts the anticonvulsant effects and may precipitate seizures 2
• Flumazenil is particularly risky in long-term benzodiazepine users and cyclic antidepressant overdose 1

Follow-Up Anticonvulsant Therapy

• Diazepam should be followed immediately by a long-acting anticonvulsant such as phenytoin or fosphenytoin 2
• Diazepam is rapidly redistributed and seizures often recur within 15–20 minutes 2
• Once acute symptomatology is controlled, patients may be placed on oral therapy if further treatment is required 1

Common Pitfalls to Avoid

• Do not exceed 30 mg cumulative dose in adults during the initial treatment period 1
• Do not administer faster than 1 minute per 5 mg, as rapid injection increases seizure and respiratory depression risk 2, 1
• Do not mix or dilute diazepam with other solutions or drugs in syringe or infusion container 1
• Do not rely on diazepam alone—always follow with a long-acting anticonvulsant 2
• Do not use in patients with established IV access if intramuscular midazolam is available, as IM midazolam has demonstrated superior effectiveness compared to IV lorazepam in prehospital settings 3

Context: Second-Line Agents After Benzodiazepines

If seizures continue despite optimal benzodiazepine dosing, emergency physicians should administer fosphenytoin, levetiracetam, or valproate as second-line agents with similar efficacy. 4 The ESETT trial demonstrated that cessation of status epilepticus occurred in 47% with levetiracetam, 45% with fosphenytoin, and 46% with valproate, with no significant differences in efficacy or safety outcomes 4.